市場調查報告書

胃輕癱:至2030的流行病學預測

Gastroparesis - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955866
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
胃輕癱:至2030的流行病學預測 Gastroparesis - Epidemiology Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

世界主要7個國家(美國,德國、法國、義大利、西班牙、英國、日本)的胃輕癱的患病數,2017年為3,369萬400件,今後預計增加。各國中美國最多,2017年為1,301萬9,321件。在歐洲5個國家中,德國最多,其次是西班牙和義大利。

本報告提供世界主要7個國家(美國,德國、法國、義大利、西班牙、英國、日本)的胃輕癱的相關調查,提供疾病概要,各國流行病學,患者人口的統計等資訊。

目錄

第1章 主要洞察

第2章 胃輕癱:一看就明白的市場概要

  • 整體市場佔有率:2017年的胃輕癱的分佈
  • 整體市場佔有率:2030年的胃輕癱的分佈

第3章 摘要整理

第4章 SWOT分析

第5章 疾病的背景和概要

  • 簡介
  • 基於胃輕癱的種類:原因
    • 特發性胃輕癱(IG)
    • 糖尿病性胃輕癱(DGp)
    • 醫原性及術後胃輕癱
  • 臨床症狀
  • 胃輕癱的機制或病理生理學
  • 胃輕癱的診斷

第6章 認證機關

第7章 流行病學和患者人口

  • 主要調查結果
  • 流行病學調查手法
  • 盛行率
  • 類型固有的盛行率
  • 性別固有的盛行率
  • 重病度固有的盛行率
  • 確診的病患人口的總合

第8章 美國的流行病學

第9章 歐洲5個國家的流行病學

  • 德國的流行病學
  • 法國的流行病學
  • 義大利的流行病學
  • 西班牙的流行病學
  • 英國的流行病學

第10章 日本的流行病學

目錄
Product Code: DIEI0085

DelveInsight's 'Gastroparesis - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gastroparesis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroparesis Understanding

Gastroparesis, which is a translated meaning of "stomach paralysis", is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia makes the diagnosis of Gastroparesis.

Gastroparesis may be idiopathic or associated with diabetes mellitus, may occur after a medical intervention (iatrogenic or post-surgical), or with neurological disorders, it can also occur after a viral or bacterial infection, such as Salmonella gastroenteritis. Interestingly, Helicobacter pylori infection of the stomach does not seem to influence gastric emptying or accommodation but may be associated with heightened sensitivity in patients with functional dyspepsia.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

Gastroparesis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Gastroparesis, Gender-specific Prevalence of Gastroparesis, Severity-specific Prevalence of Gastroparesis, Type-specific Prevalence of Gastroparesis and Total Diagnosed Prevalent Population of Gastroparesis a scenario of Gastroparesis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Gastroparesis Detailed Epidemiology Segmentation

  • The total prevalent population of gastroparesis in the 7MM is expected to rise from 33,690,400 in 2017.
  • As per estimates, the highest prevalence of gastroparesis was observed in the United States with 13,019,321 cases in 2017, which is likely to rise by 2030.
  • As per DelveInsight's analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.
  • According to DelveInsight's analysis, it has been observed that mild cases are more prominent in comparison to moderate-to-severe. In the United States, 7,811,592 mild cases were observed in 2017, i.e., 60% of the gastroparesis patient pool. Additionally, moderate-to-severe accounted for 40% of the gastroparesis patient pool.
  • Among the major types of gastroparesis, i.e., idiopathic, diabetic and post-surgical gastroparesis, idiopathic gastroparesis accounts for a higher number of gastroparesis cases.
  • Among the EU5 countries, in 2017, Germany had the highest prevalent population of gastroparesis followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis.

Scope of the Report:

  • The report covers the descriptive overview of Gastroparesis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Gastroparesis.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Gastroparesis, Total Diagnosed and Treated Cases of Gastroparesis.

Report Highlights:

  • Eleven-Year Forecast of Gastroparesis
  • 7MM Coverage
  • Total Prevalence of Gastroparesis
  • Gender-specific Prevalence of Gastroparesis
  • Severity-specific Prevalence of Gastroparesis
  • Type-specific Prevalence of Gastroparesis and
  • Total Diagnosed Prevalent Population of Gastroparesis

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Gastroparesis?
  • What is the historical Gastroparesis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Gastroparesis at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastroparesis?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Gastroparesis during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The Gastroparesis report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Gastroparesis market.
  • Quantify patient populations in the 7MM Gastroparesis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the specific type of Gastroparesis that presents the best opportunities for Gastroparesis therapeutics in each of the markets covered.
  • The Gastroparesis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Gastroparesis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Gastroparesis: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
  • 2.2. Total Market Share (%) Distribution of Gastroparesis in 2030

3 Executive Summary

4 SWOT Analysis

5 Gastroparesis: Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Types of Gastroparesis: Based on Causes
    • 5.2.1 Idiopathic Gastroparesis (IG)
    • 5.2.2 Diabetic Gastroparesis (DGp)
    • 5.2.3 Iatrogenic and Postsurgical Gastroparesis
  • 5.3 Clinical Signs and Symptoms
  • 5.4 Mechanisms or pathophysiology of gastroparesis
  • 5.5 Diagnosis of Gastroparesis

6 Recognized Establishments

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Epidemiology Methodology
  • 7.3 Total Prevalence of Gastroparesis in the 7MM
  • 7.4 Type-specific Prevalence of Gastroparesis in the 7MM
  • 7.5 Gender-specific Prevalence of Gastroparesis in the 7MM
  • 7.6 Severity-specific Prevalence of Gastroparesis in the 7MM
  • 7.7 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

8 United States Epidemiology

  • 8.1 Assumptions and Rationale
  • 8.2 Total Prevalence of Gastroparesis in the United States
  • 8.3 Type-specific Prevalence of Gastroparesis in the United States
  • 8.4 Gender-specific Prevalence of Gastroparesis in the United States
  • 8.5 Severity-specific Prevalence of Gastroparesis in the United States
  • 8.6 Total Diagnosed Prevalence of Gastroparesis in the United States

9 EU5 Epidemiology

  • 9.1 Germany Epidemiology
    • 9.1.1 Total Prevalence of Gastroparesis in Germany
    • 9.1.2 Type-specific Prevalence of Gastroparesis in Germany
    • 9.1.3 Gender-specific Prevalence of Gastroparesis in Germany
    • 9.1.4 Severity-specific Prevalence of Gastroparesis in Germany
    • 9.1.5 Total Diagnosed Prevalence of Gastroparesis in Germany
  • 9.2 France Epidemiology
    • 9.2.1 Total Prevalence of Gastroparesis in France
    • 9.2.2 Type-specific Prevalence of Gastroparesis in France
    • 9.2.3 Gender-specific Prevalence of Gastroparesis in France
    • 9.2.4 Severity-specific Prevalence of Gastroparesis in France
    • 9.2.5 Total Diagnosed Prevalence of Gastroparesis in France
  • 9.3 Italy Epidemiology
    • 9.3.1 Total Prevalence of Gastroparesis in Italy
    • 9.3.2 Type-specific Prevalence of Gastroparesis in Italy
    • 9.3.3 Gender-specific Prevalence of Gastroparesis in Italy
    • 9.3.4 Severity-specific Prevalence of Gastroparesis in Italy
    • 9.3.5 Total Diagnosed Prevalence of Gastroparesis in Italy
  • 9.4 Spain Epidemiology
    • 9.4.1 Total Prevalence of Gastroparesis in Spain
    • 9.4.2 Type-specific Prevalence of Gastroparesis in Spain
    • 9.4.3 Gender-specific Prevalence of Gastroparesis in Spain
    • 9.4.4 Severity-specific Prevalence of Gastroparesis in Spain
    • 9.4.5 Total Diagnosed Prevalence of Gastroparesis in Spain
  • 9.5 United Kingdom Epidemiology
    • 9.5.1 Total Prevalence of Gastroparesis in the United Kingdom
    • 9.5.2 Type-specific Prevalence of Gastroparesis in the United Kingdom
    • 9.5.3 Gender-specific Prevalence of Gastroparesis in the United Kingdom
    • 9.5.4 Severity-specific Prevalence of Gastroparesis in the United Kingdom
    • 9.5.5 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

10 Japan

  • 10.1 Assumptions and Rationale
  • 10.2 Total Prevalence of Gastroparesis in Japan
  • 10.3 Type-specific Prevalence of Gastroparesis in Japan
  • 10.4 Gender-specific Prevalence of Gastroparesis in Japan
  • 10.5 Severity-specific Prevalence of Gastroparesis in Japan
  • 10.6 Total Diagnosed Prevalence of Gastroparesis in Japan

List of Tables

  • Table 1: Summary of Gastroparesis- Epidemiology, and Key Events (2017-2030)
  • Table 2: Pathogenesis and Etiology of Gastroparesis
  • Table 3: Total Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Table 4: Type-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Table 5: Gender-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Table 6: Severity-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Table 7: Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2030)
  • Table 8: Total Prevalence of Gastroparesis in the United States (2017-2030)
  • Table 9: Type-specific Prevalence of Gastroparesis in the United States (2017-2030)
  • Table 10: Gender-specific Prevalence of Gastroparesis in the United States (2017-2030)
  • Table 11: Severity-specific Prevalence of Gastroparesis in the United States (2017-2030)
  • Table 12: Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2030)
  • Table 13: Total Prevalence of Gastroparesis in Germany (2017-2030)
  • Table 14: Type-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Table 15: Gender-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Table 16: Severity-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Table 17: Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2030)
  • Table 18: Total Prevalence of Gastroparesis in France (2017-2030)
  • Table 19: Type-specific Prevalence of Gastroparesis in France (2017-2030)
  • Table 20: Gender-specific Prevalence of Gastroparesis in France (2017-2030)
  • Table 21: Severity-specific Prevalence of Gastroparesis in France (2017-2030)
  • Table 22: Total Diagnosed Prevalence of Gastroparesis in France (2017-2030)
  • Table 23: Total Prevalence of Gastroparesis in Italy (2017-2030)
  • Table 24: Type-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Table 25: Gender-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Table 26: Severity-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Table 27: Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2030)
  • Table 28: Total Prevalence of Gastroparesis in Spain (2017-2030)
  • Table 29: Type-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Table 30: Gender-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Table 31: Severity-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Table 32: Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2030)
  • Table 33: Total Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Table 34: Type-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Table 35: Gender-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Table 36: Severity-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Table 37: Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Table 38: Total Prevalence of Gastroparesis in Japan (2017-2030)
  • Table 39: Type-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Table 40: Gender-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Table 41: Severity-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Table 42: Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis of Gastroparesis
  • Figure 2: Types of Gastroparesis Based on Causes
  • Figure 3: Etiologies of Gastroparesis
  • Figure 4: Interaction of Interstitial Cells of Cajal (ICC) Cells and Neuronal Nitric Oxide Synthase (nNOS) Signaling for Normal Gastric Emptying (GE)
  • Figure 5: Mechanisms of Gastric Accommodation and Emptying
  • Figure 6: Diagnosis of Gastroparesis
  • Figure 7: Total Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Figure 8: Type-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Figure 9: Gender-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Figure 10: Severity-specific Prevalence of Gastroparesis in the 7MM (2017-2030)
  • Figure 11: Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2030)
  • Figure 12: Total Prevalence of Gastroparesis in the United States (2017-2030)
  • Figure 13: Type-specific Prevalence of Gastroparesis in the United States (2017-2030)
  • Figure 14: Gender-specific Prevalence of Gastroparesis in the US (2017-2030)
  • Figure 15: Severity-specific Prevalence of Gastroparesis in the United States (2017-2030)
  • Figure 16: Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2030)
  • Figure 17: Total Prevalence of Gastroparesis in Germany (2017-2030)
  • Figure 18: Type-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Figure 19: Gender-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Figure 20: Severity-specific Prevalence of Gastroparesis in Germany (2017-2030)
  • Figure 21: Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2030)
  • Figure 22: Total Prevalence of Gastroparesis in France (2017-2030)
  • Figure 23: Type-specific Prevalence of Gastroparesis in France (2017-2030)
  • Figure 24: Gender-specific Prevalence of Gastroparesis in France (2017-2030)
  • Figure 25: Severity-specific Prevalence of Gastroparesis in France (2017-2030)
  • Figure 26: Total Diagnosed Prevalence of Gastroparesis in France (2017-2030)
  • Figure 27: Total Prevalence of Gastroparesis in Italy (2017-2030)
  • Figure 28: Type-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Figure 29: Gender-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Figure 30: Severity-specific Prevalence of Gastroparesis in Italy (2017-2030)
  • Figure 31: Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2030)
  • Figure 32: Total Prevalence of Gastroparesis in Spain (2017-2030)
  • Figure 33: Type-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Figure 34: Gender-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Figure 35: Severity-specific Prevalence of Gastroparesis in Spain (2017-2030)
  • Figure 36: Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2030)
  • Figure 37: Total Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Figure 38: Type-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Figure 39: Gender-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Figure 40: Severity-specific Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Figure 41: Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2030)
  • Figure 42: Total Prevalence of Gastroparesis in Japan (2017-2030)
  • Figure 43: Type-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Figure 44: Gender-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Figure 45: Severity-specific Prevalence of Gastroparesis in Japan (2017-2030)
  • Figure 46: Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2030)